Literature DB >> 2648930

Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q.

R DeVore1, J Whitlock, J D Hainsworth, D H Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2648930     DOI： 10.7326/0003-4819-110-9-740

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  13 in total

1.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Authors:  Amanda C Gentry; Steven L Pitts; Michael J Jablonsky; Christian Bailly; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2011-03-28       Impact factor: 3.162

2.  Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Authors:  M M Hawkins; L M Wilson; M A Stovall; H B Marsden; M H Potok; J E Kingston; J M Chessells
Journal:  BMJ       Date:  1992-04-11

Review 3.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.

Authors:  Lorena Infante Lara; Sabine Fenner; Steven Ratcliffe; Albert Isidro-Llobet; Michael Hann; Ben Bax; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2018-03-16       Impact factor: 16.971

5.  The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds.

Authors:  C Caslini; A S Alarcòn; J L Hess; R Tanaka; K G Murti; A Biondi
Journal:  Leukemia       Date:  2000-11       Impact factor: 11.528

Review 6.  Secondary acute lymphoblastic leukemia with t (4;11): report on two cases and review of the literature.

Authors:  E Auxenfants; P Morel; J L Lai; C Sartiaux; L Detourmignies; F Bauters; P Fenaux
Journal:  Ann Hematol       Date:  1992-09       Impact factor: 3.673

Review 7.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

8.  Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.

Authors:  Ryan P Bender; Neil Osheroff
Journal:  Chem Res Toxicol       Date:  2007-05-22       Impact factor: 3.739

Review 9.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

Review 10.  Pharmacodynamics and long-term toxicity of etoposide.

Authors:  K Kobayashi; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.